Prescription persistence and safety of antipsychotic medication: A national registry-based 3-year follow-up

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 911-917

  Gjerden, Pål ^a   Slørdal, Lars ^b,c   Bramness, Jørgen G ^d,e  

^a TELEMARK HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Adverse effects; Anticholinergic agents; Antipsychotic agents; Drug utilisation

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOPENTHIXOL; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ARTICLE; DATA BASE; DATA EXTRACTION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MORTALITY; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT;

ADULT; AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CHLORPROTHIXENE; CHOLINERGIC ANTAGONISTS; CLOPENTHIXOL; CLOZAPINE; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; LOGISTIC MODELS; MALE; METHOTRIMEPRAZINE; MIDDLE AGED; MORTALITY; NORWAY; ODDS RATIO; PIPERAZINES; REGISTRIES; THIAZOLES;

EID: 77956191270     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0839-9     Document Type: Article

References (29)

1. R Tandon RH Belmaker WF Gattaz JJ Lopez-Ibor Jr A Okasha B Singh DJ Stein J-P Olie WW Fleishhacker H-J Moeller 2008 World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia Schizophr Res 100 20 38 10.1016/j.schres.2007.11.033 18243663
2. S Opjordsmoen I Melle S Friis U Haahr JO Johannessen TK Larsen BR Rund E Simonsen P Vaglum TH McGlashan 2009 Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics Early Interv Psychiatry 3 58 65 10.1111/j.1751-7893.2008.00103.x
3. L Sikich JA Frazier J McClellan RL Findling B Vitiello L Ritz D Ambler M Puglia AE Maloney E Michael S De Jong K Slifka N Noyes S Hlastala L Pierson NK McNamara D Delporto-Bedoya R Anderson RA Hamer JA Lieberman 2008 Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study Am J Psychiatry 165 1420 1431 10.1176/appi.ajp.2008.08050756 18794207
4. G Morken JH Widen RW Grawe 2008 Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia BMC Psychiatry 8 32 10.1186/1471-244X-8-32 10.1186/1471-244X-8-32 18447935
5. FD Gianfresco M Sajatovic K Rajagopalan R-H Wang 2008 Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder Clin Ther 30 7 1358 1374 10.1016/S0149-2918(08)80062-8
6. S Heres J Davis K Maino E Jetzinger W Kissling S Leucht 2006 Why olanzapine beats risperidone, risperidone beats quetiapine and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics Am J Psychiatry 163 2 185 195 10.1176/appi.ajp.163.2.185 16449469
7. S Leucht C Corves D Arbter RR Engel C Li JM Davis 2009 Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 31 41 10.1016/S0140-6736(08)61764-X 1:CAS:528:DC%2BD1MXht1Wqsw%3D%3D 19058842
8. WW Fleischacker GM Goodwin 2009 Effectiveness as an outcome measure for treatment trials in psychiatry World Psychiatry 8 23 27
9. DC Owens 2008 How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia Adv Psychiatr Treat 14 17 28 10.1192/apt.bp.107. 003970
10. H Ascher-Svanum AW Nyhuis DE Faries L Heiler BJ Kinon 2008 Treatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotics during a one-year treatment for schizophrenia Clin Schizophr Relat Psychoses 2 3 226 234 10.3371/CSRP.2.3.4
11. BJ Kinon H Liu-Seifert DH Adams L Citrome 2006 Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia J Clin Psychopharmacol 26 632 637 10.1097/01.jcp.0000245563.06660. 0f 1:CAS:528:DC%2BD28Xht1Smt7nO 17110821
12. P Gjerden L Slørdal JG Bramness 2009 Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents Eur J Clin Pharmacol 65 12 1229 1235 10.1007/s00228-009-0696-6 1:CAS:528:DC%2BD1MXhsVKnsbbL
13. K Furu H Strøm M Rønning S Skurtveit A Engedal A Tverdal 2005 The Norwegian Prescription database (NorPD): new register for pharmacoepidemiological research covering a whole nation Pharmacoepidemiol Drug Safe 14 Suppl 2 S48
14. WHO Collaborating Centre for Drug Statistics Methodology (2005) Guidelines for ATC classification and DDD assignment. WHO, Oslo
15. HA Nasrallah T White AT Nasrallah 2004 Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol Am J Geriatr Psychiatry 12 437 439 15249282
16. J Hollis S Touyz D Grayson L Forrester 2006 Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows Aust N Z J Psychiatry 40 11-12 981 986 17054566
17. J Tiihonen J Lønnquist K Wahlbeck T Klaukka L Niskanen A Tanskanen J Haukka 2009 11-year follow-up of mortality in patients with scicophrenia: a population-based cohort study (FIN11 study) Lancet 374 620 627 10.1016/S0140-6736(09)60742-X 19595447
18. JA Lieberman FP Bymaster HY Meltzer AY Deutch GE Duncan CE Marx JR Aprille DS Dwyer X-M Li SP Mahadik RS Duman JH Porter JS Modica-Napolitano SS Newton JG Csernansky 2008 Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation and neuroprotection Pharmacol Rev 60 358 403 10.1124/pr.107.00107 1:CAS:528:DC%2BD1MXmsVCht70%3D 18922967
19. F Casadebaig A Philippe 1999 Mortality among schizophrenic patients Encephale 25 4 329 337 1:STN:280:DC%2BD3c%2FhtlCisA%3D%3D 10546089
20. M Vythilingam J Chen JD Bremner CM Mazure PK Maciejewski JC Nelson 2003 Psychotic depression and mortality Am J Psychiatry 160 574 576 10.1176/appi.ajp.160.3.574 12611843
21. SR Kjosavik S Ruths S Hunskaar 2009 Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database Pharmacoepidemiol Drug Safe 18 572 578 10.1002/pds.1756
22. van Kammen DP, Marder SR (2005) Serotonin-dopamine antagonists (atypical or second-generation antipsychotics). In: Sadock JB, Sadock VA (eds) Kaplan & Sadock's comprehensive textbook of psychiatry. Lippincott Williams & Wilkins, Philadelphia, pp 2914-2938
23. P Gjerden L Slørdal 1998 Antikolinerge antiparkinsonmedikamenters kliniske farmakologi Tidsskr Nor Laegeforen 118 1 53 55 1:STN:280: DyaK1c7kt12isw%3D%3D 9481912
24. M Stewart 2001 Towards a global definition of patient centred care BMJ 322 444 445 10.1136/bmj.322.7284.444 1:STN:280:DC%2BD3M7otlylsw%3D%3D 11222407
25. PE Deegan RE Drake 2006 Shared decision making and medication management in the recovery process Psychiatr Serv 57 1636 1638 10.1176/appi.ps.57.11.1636 17085613
26. [No authors listed] (1990) Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on aspects of mental illness. Br J Psychiatry 156:412
27. P Gjerden JG Bramness L Slørdal 2008 Effect of warnings in a medical journal on the use of orphenadrine J Eval Clin Pract 14 615 617 10.1111/j.1365-2753.2007.00912.x 18462287
28. I Castberg A Reimers P Sandvik T Aamo O Spigset 2006 Adverse drug reactions of antidepressants and antipsychotics: experience, knowledge and attitudes among Norwegian psychiatrists Nord J Psychiatry 60 227 233 10.1080/08039480600636494 16720514
29. D Cooper J Moisan J-P Gregoire 2007 Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia J Clin Psychiatry 68 818 825 10.4088/JCP.v68n0601 1:CAS:528:DC%2BD2sXot1eitrs%3D 17592904